With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Advanced Therapeutics for Pediatric Cancer||Seattle Children's Hospital and Regional Medical Center / Julie Park, MD||Phase I/II Infrastructure Grants||2008||Washington|
|Adoptive immunotherapy using clinical-grade T cells.||University of Texas M.D. Anderson Cancer Center / Laurence Cooper, MD, PhD||Innovation Grants||2007||Texas|
|Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML||Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD||Reach Grants||2015||California|
|Adoptive Cell Therapy Targeting Antigen Escape Variants in Childhood High Grade Glioma||Baylor College of Medicine / Meenakshi Hegde||Young Investigator Grants||2012||Texas|
|Adaptation of acute lymphoblastic leukemia (ALL) to the post-transplant allogeneic environment.||University of Rochester / Craig Mullen||Innovation Grants||2009||New York|
|Accessing Combinatorial Effect of PARP Inhibitor with DNA Damaging Agent in Rhabdomyosarcoma at Single Cell Resolution||Massachusetts General Hospital / Chuan Yan, PhD||Young Investigator Grants||2018||Massachusetts|
|Accelerating Access to Cellular Therapies for the Treatment of Childhood Malignancies||Seattle Children's Hospital and Regional Medical Center / Julie Park, MD||Phase I/II Infrastructure Grants||2013||Washington|
|Aberrant DNA methylation in Ewing sarcoma.||Fred Hutchinson Cancer Research Center / Scott Borinstein||Young Investigator Grants||2009||Washington|
|A Translational Approach to Identify Drugs with Specific Activity Against EZH2 Mutant High Risk T-ALLs and ETP ALLs that Overexpress the JDP2 bZIP Transcription Factor||Dana-Farber Cancer Institute / Shuning He, PhD||Young Investigator Grants||2015||Massachusetts|
|A Role for Notch in Self-renewal in Embryonal Rhabdomyosarcoma||Massachusetts General Hospital / Myron Ignatius, PhD||'A' Award Grants||2012||Massachusetts|